Xeris Biopharma Holdings (XERS) Short term Debt (2023 - 2025)

Xeris Biopharma Holdings has reported Short term Debt for 3 years, with the latest figure at $12.0 million in Q1 2025.

• For the quarter ending Q1 2025, Short term Debt rose 1071.3% year-over-year to $12.0 million; the trailing twelve-month figure through Mar 2025 stood at $12.0 million (up 1071.3% YoY), and the FY2024 full-year result was $15.1 million, changed N/A from the prior year.
• Short term Debt for Q1 2025 stood at $12.0 million, down from $15.1 million in the prior quarter.
• The five-year high for Short term Debt was $17.5 million in Q3 2023, with the low at $420000.0 in Q2 2024.
• Historically, Short term Debt has averaged $11.1 million across 3 years, with a median of $15.0 million in 2023.
• Annual changes were most pronounced in 2024 — Short term Debt plunged 97.48% — and 2025, when it jumped 1071.3%.
• Xeris Biopharma Holdings' Short term Debt stood at $17.5 million in 2023, then decreased by 13.79% to $15.1 million in 2024, then slipped by 20.81% to $12.0 million in 2025.
• The last three Short term Debt figures came in at $12.0 million (Q1 2025), $15.1 million (Q4 2024), and $420000.0 (Q2 2024), per Business Quant data.